CDMO Cambrex snatches Halo Pharma, getting 2 plants and 425 employees

Halo Pharma plant
This plant in Montreal is one of two that Cambrex will get with its $425 million deal to buy Halo Pharma. (Cambrex)

There is more M&A action in the CDMO arena this week as New Jersey-based Cambrex has struck a deal to buy Halo Pharma, picking up two manufacturing facilities in the process.

Cambrex Monday said it has agreed to pay $425 million to buy the dosage-form CDMO from SK Capital, a firm with a number of CDMO holdings.

“Halo’s expertise in oral solids, liquids, creams and ointments fits well with our small molecule API business and brings a substantial new customer base and pipeline of small molecule products,” Steve Klosk, Cambrex CEO said in a statement.

Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This on-demand webinar discusses the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

RELATED: Halo agrees to buy Teva's Montreal facility

Halo operates manufacturing sites in Whippany, New Jersey, and Montreal, Québec, Canada, comprising a total of 430,000 square feet of plant space. Its 450-person workforce will join Cambrex’s 1,200 employees across the United States and Europe. Cambrex said Halo is expected to generate more than $100 million in annual revenue in 2018.

SK Capital has been in the midst of a lot of consolidation in the CDMO market. A year ago Perrigo sold off its active pharmaceutical business to the investment group for $110 million.

Other deals include the recent June deal by France’s Novacap to buy Boston-area-based CDMO PCI Synthesis. Also in June, Sweden’s Recipharm struck a $60.2 million deal with Sanofi to buy the French drugmaker’s contract inhalation drug business and plant in the U.K.

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.